Cirrus Therapeutics, the University of Bristol, and London’s Global University Institute of Ophthalmology have unveiled a revolutionary treatment for age-related macular degeneration (AMD), the leading cause of vision loss among older adults. Highlighted on the cover of Science Translational Medicine, this groundbreaking research shows that increasing levels of a specific protein, IRAK-M, in retinal cells could offer a highly effective therapy for AMD.
AMD severely impacts vision, starting with blurred sight or a central black dot, which can expand, leading to complete central vision loss. Currently, around 200 million people worldwide suffer from AMD, with projections suggesting this number will rise to 288 million by 2040 due to aging populations. The exact cause of AMD is complex, involving a mix of aging, environmental, and lifestyle factors.
Continue reading… “New Breakthrough in Treating Age-Related Macular Degeneration”